Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 24 Feb 2022 12:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Resolution to increase the share capital in connection with the subsequent offering and terms of the subsequent offering | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Feb 2022 09:57 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2021 Results Presentation and Webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Feb 2022 10:13 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Extraordinary general meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Jan 2022 10:38 CET |
NORDIC NANOVECTOR | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Jan 2022 10:38 CET |
NORDIC NANOVECTOR | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 24 Jan 2022 16:45 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Notice of extraordinary general meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Jan 2022 11:18 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Share capital increase registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Jan 2022 08:43 CET |
NORDIC NANOVECTOR | Mandatory notification of trade | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Jan 2022 07:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Ex subsequent offering today | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2022 22:23 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Key information regarding potential subsequent offering | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2022 22:20 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Private placement of new shares successfully placed | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2022 16:57 CET |
NORDIC NANOVECTOR | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 19 Jan 2022 16:57 CET |
NORDIC NANOVECTOR | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Jan 2022 16:54 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA - Contemplated private placement of new shares | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Jan 2022 19:22 CET |
NORDIC NANOVECTOR | Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Dec 2021 09:39 CET |
NORDIC NANOVECTOR | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Dec 2021 09:39 CET |
NORDIC NANOVECTOR | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 23 Dec 2021 07:30 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Financial Calendar for 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 16 Dec 2021 07:30 CET |
NORDIC NANOVECTOR | Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Dec 2021 16:30 CET |
NORDIC NANOVECTOR | Nordic Nanovector to Present at DNB's 12[th] Nordic Healthcare Conference | 20103010 Biotechnology | Non-regulatory press releases |
| 07 Dec 2021 07:30 CET |
NORDIC NANOVECTOR | Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021 | 20103010 Biotechnology | Non-regulatory press releases |
| 30 Nov 2021 07:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Nov 2021 08:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: R&D Day to be virtual via live webcast only | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Nov 2021 11:26 CET |
NORDIC NANOVECTOR | Correction: Nordic Nanovector ASA: Invitation to attend R&D Day - clarification of CMO title | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Nov 2021 07:04 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to attend R&D Day | 20103010 Biotechnology | Non-regulatory press releases |
| 18 Nov 2021 07:01 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Results for the Third Quarter 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Nov 2021 07:00 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Resultat for tredje kvartal 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Nov 2021 10:30 CET |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to Third Quarter 2021 Results Presentation and Webcast | 20103010 Biotechnology | Non-regulatory press releases |
| 09 Nov 2021 17:54 CET |
NORDIC NANOVECTOR | Nordic Nanovector supports The Health Policy Partnership's initiative to improve appropriate readiness for radioligand therapy (radioimmunotherapy) in lymphoma | 20103010 Biotechnology | Non-regulatory press releases |
| 08 Nov 2021 18:20 CET |
NORDIC NANOVECTOR | Nordic Nanovector appoints experienced biotech executive Pierre Dodion MD as Chief Medical Officer | 20103010 Biotechnology | Non-regulatory press releases |
| 19 Oct 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector enters research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell approach | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Sep 2021 10:25 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA - allocation of PSUs | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 14 Sep 2021 18:08 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Aug 2021 07:01 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Results for the Second Quarter and First Half 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Aug 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Resultat for andre kvartal og første halvår 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Aug 2021 08:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2021 Results Presentation Webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Aug 2021 23:11 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jul 2021 07:30 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2021 18:19 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Share capital increase registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 Jun 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Jun 2021 17:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Increase of share capital | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Jun 2021 16:59 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 18 Jun 2021 08:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Increase of share capital | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Jun 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 May 2021 07:01 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Results for the First Quarter 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 May 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Resultat for første kvartal 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 May 2021 07:00 CEST |
NORDIC NANOVECTOR | Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 Apr 2021 15:13 CEST |
NORDIC NANOVECTOR | Nordic Nanovector ASA: Annual General Meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |